SCHEMBL4660296

SCHEMBL4660296

CCOC(=O)c1c(OC)c2ncc(Cc3ccc(F)cc3CN(C)C)cc2n(C)c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 4/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
POLB P06746 1/20 0.34
PABPC1 P11940 1/20 0.34
GRIN2B Q13224 4/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
HPGD P15428 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
TACR1 P25103 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
GABRA1 P14867 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14067537 0.93 ALDH1A1 (0.37) LMNAKDM4EALDH1A1MEN1KMT2A
SCHEMBL4900462 0.93 TACR1 (0.35) LMNAKDM4EALDH1A1MEN1KMT2A
SCHEMBL4907399 0.92 GRIN2B (0.36) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL4907852 0.92 ALDH1A1 (0.38) LMNAKDM4EALDH1A1MEN1KMT2A
SCHEMBL4904317 0.91 MEN1 (0.35) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL4903149 0.91 ALDH1A1 (0.36) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL4907766 0.91 ALDH1A1 (0.36) LMNAKDM4EALDH1A1MEN1KMT2A
SCHEMBL4661974 0.90 KDM4E (0.35) LMNAKDM4EALDH1A1MEN1KMT2A
SCHEMBL4909342 0.90 ALDH1A1 (0.35) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL4894901 0.90 KDM4E (0.42) LMNAKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214527-A1 Hiv Integrase Inhibitors SHIONOGI & CO. LTD (JP) 2008-09-04 US disclosed
EP-1910363-A2 HIV INTEGRASE INHIBITORS SmithKline Beecham Corporation (US) 2008-04-16 EP disclosed
WO-2007019098-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214527-A1 Hiv Integrase Inhibitors API5, ING2, SAMHD1 LMNA 4059/4885KDM4E 1139/4885ALDH1A1 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.